Urs Wiedemann is a panelist on a workshop entitled “Let’s get personal: Advances in precision medicine are changing the way we identify and treat disease.”
CRA is a silver sponsor for this annual conference.
For more information on this event, click here.
Keytruda and PD(L)1: Life after programmed death (part 2)
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...